12P DESTINY-Breast respond HER2-low Europe non-interventional study of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer (mBC): Update on baseline characteristics and anti-emetic treatment
Annals of Oncology · 2026-12 · 37 · S377-S378
DOI: 10.1016/j.annonc.2026.08.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Oncology, 2026-12. Verfasst von J-Y. Pierga und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Pierga, J., Duhoux, F., Egle, D., Saenz, J. G., Penault-Llorca, F., Valachis, A., Wildiers, H., Zaman, K., Laeis, P., Lucerna, M., Edlich, B., & Guarneri, V. (2026). 12P DESTINY-Breast respond HER2-low Europe non-interventional study of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer (mBC): Update on baseline characteristics and anti-emetic treatment. Annals of Oncology, 37, S377-S378. https://doi.org/10.1016/j.annonc.2026.08.021
Vancouver
Pierga J, Duhoux F, Egle D, Saenz JG, Penault-Llorca F, Valachis A, et al. 12P DESTINY-Breast respond HER2-low Europe non-interventional study of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer (mBC): Update on baseline characteristics and anti-emetic treatment. Annals of Oncology. 2026;37:S377-S378. doi:10.1016/j.annonc.2026.08.021
BibTeX
@article{Pierga2026,
author = {Pierga, J-Y. and Duhoux, F.P. and Egle, D. and Saenz, J.Á. García and Penault-Llorca, F. and Valachis, A. and Wildiers, H. and Zaman, K. and Laeis, P. and Lucerna, M. and Edlich, B. and Guarneri, V.},
title = {12P DESTINY-Breast respond HER2-low Europe non-interventional study of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer (mBC): Update on baseline characteristics and anti-emetic treatment},
journal = {Annals of Oncology},
year = {2026},
volume = {37},
pages = {S377--S378},
doi = {10.1016/j.annonc.2026.08.021}
}
EUVIMED